Weekly review: Extended labels, T1D inheritance data, and more
Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, July 29, to Friday, August 2, 2024), and click on each link to read and watch anything you may have missed.
1.) Palforzia receives expanded label to treat toddlers with peanut allergy
With the expanded label, Palforzia is now approved to treat individuals aged 1 to 17 years with a confirmed peanut allergy diagnosis, after the treatment was originally approved in 4-to-17-year-olds in January 2020.
Click here for the full article.
2.) Maternal obesity linked to increased risk of sudden unexpected infant death
A recent study reveals a direct association between higher maternal body mass index and the risk of sudden unexpected infant death, underscoring the need for further research into the causal mechanisms.
Click here for the full article.
3.) Children more likely to inherit type 1 diabetes from fathers than mothers
"Taken together, our findings suggest the relative protection associated with having a mother versus father with type 1 diabetes is a long-term effect that extends into adult life," stated study investigators.
Click here for additional study results and commentary.
4.) Xembify receives expanded label for treatment-naïve primary humoral immunodeficiencies patients
With the decision from the federal agency, the company's 20% subcutaneous immunoglobulin (SCIg) becomes the first to include the extended label, which will allow patients to begin SCIg therapy without first having intravenous administration, according to a press release from Grifols.
Click here for additional approval details.
5.) NICU hospital-onset bacteremia linked to increased mortality, risk differs with birth weight
Erica Prochaska, MD, highlights a recent study that aimed to estimate the rate of HOB among infants admitted to the NICU, measure the association of HOB risk with birth weight group and postnatal age, and estimate HOB-attributable mortality.
Dupilumab (Dupixent) becomes first FDA-approved drug for adolescent CRSwNP
September 13th 2024The landmark indication is supported by a couple of pivotal trials assessing dupilumab for patients with chronic rhinosinusitis with nasal polyps, as well as a pediatric severe asthma trial assessing the biologic.
